Empower Pharmacy sermorelin review: products, costs, and FDA records

What the pharmacy currently lists

The injectable product reference describes sermorelin acetate injection. A separate ODT reference lists an orally disintegrating tablet available through the 503A pharmacy, with a catalog strength of 1,000 micrograms per tablet. That is a product description, not a recommendation to take that amount.

The pages establish that Empower markets these formats. They do not establish that every state, clinic, or patient can access both, or that the catalog reflects the exact preparation a prescriber will select. Before paying, ask for the active ingredients, route, concentration or strength, quantity, and dispensing entity in writing.

An ODT dissolves in the mouth, but dissolution is only one step. How much medicine reaches the bloodstream and whether it produces a useful clinical result are different questions. Our oral bioavailability guide explains why an injection study cannot establish an equivalent effect for a contemporary compounded tablet.

How a pharmacy differs from a treatment program

A pharmacy prepares or dispenses medication. A telehealth program may separately arrange the medical consultation, laboratory testing, follow-up, billing, and renewal process. Several organizations can therefore be involved in one prescription, even when the advertisement shows only one brand.

Ask the program who makes prescribing decisions, who dispenses the medication, and who handles a product concern after delivery. A pharmacy catalog is not a medical intake service by itself, and an account or order link does not replace a patient-specific prescribing decision. The prescription access guide explains the roles and the records to request.

Do not assume a clinic uses Empower because another patient received an Empower label. Arrangements can differ by formulation and location. The pharmacy name and address on your actual prescription are more useful than a general statement about a brand’s network.

What the published research can support

Empower’s references discuss growth-hormone physiology and studies involving different populations and formulations. Those references may help explain why someone would study sermorelin. They do not automatically validate all the outcomes advertised for every product in the catalog.

For example, a study of hormone levels is not the same as a trial showing improved strength, fewer falls, or better daily functioning in adults over 50. Animal research and historical pediatric research also cannot establish the benefit of the ODT for an older adult seeking better sleep or body composition.

Ask the prescriber which study best matches the proposed formulation, your reason for treatment, and the outcome you hope to change. Our clinical studies guide separates the exact intervention and measured outcome from broader marketing interpretations. A higher IGF-1 result should not be the only explanation of success.

FDA records require the exact facility and date

FDA issued an April 2, 2025 warning letter to Empower Pharmacy following a 2024 inspection of the operation at 7601 North Sam Houston Parkway West. The letter describes concerns involving sterile drug production and conditions that could affect product quality. It also acknowledges written responses from the firm.

A separate April 2, 2025 letter to Empower Pharma concerns the outsourcing operation at 5980 West Sam Houston Parkway North. These are distinct facility records. A reader should not combine them into a single inspection history without preserving which entity and address each document covers.

These letters deserve attention, but they do not prove that a particular patient’s sermorelin vial was contaminated. They also do not, by themselves, establish the facilities’ current correction status. The FDA compounding inspection index is a starting point for checking additional records. Ask the pharmacy for current information addressing the findings relevant to the facility preparing your prescription.

Compounding status is not product approval

The FDA distinguishes traditional compounding under section 503A from registered outsourcing facilities under section 503B. The requirements differ, and a business name may encompass more than one operation. Neither category means that a particular compounded sermorelin product has received FDA approval for safety, effectiveness, and quality.

Our compounding pharmacy guide explains those distinctions. Verify the exact pharmacy through the relevant state board using the FDA’s licensing resource. This review did not perform a state-by-state license audit or independently validate the tests for any dispensed lot.

Get a complete price before enrolling

The reviewed pages did not establish one universal patient cash price. A clinic’s monthly program charge may combine medication with services, or it may exclude consultations, laboratory tests, supplies, shipping, and renewals. A pharmacy product price and a treatment subscription are therefore not directly interchangeable.

Request the amount due today, the quantity supplied, how long that quantity is expected to last under the prescription, and every recurring charge. Also ask what happens if the clinician does not prescribe, a shipment is delayed, or treatment is stopped. The cost guide provides a worksheet for comparing complete totals without inventing a lowest-price winner.

Check the instructions and support you receive

Before the first use, confirm that the written route, amount, frequency, storage instructions, and beyond-use date are readable and consistent. An oral preparation should have its own administration instructions. Do not transfer a schedule, syringe marking, or storage period from an injectable product to an ODT.

For an injection, ask the pharmacist to explain any unfamiliar concentration or equipment. If the refill looks different, clarify it before using it. Know whom to contact about a shipping problem, unexpected symptoms, and a replacement request. Clear access to the responsible professionals is a practical part of evaluating a pharmacy-supported program.

How to use this review in a decision

Empower provides identifiable product references for two sermorelin formats, but important patient-level details remain dependent on the prescription and program. The most useful next step is a written answer about the exact preparation, its supporting evidence, the full cost, the dispensing facility, and current quality information.

You can compare those answers with the Olympia pharmacy review. Neither review is a laboratory assessment or a promise of results. A reasonable decision should leave you understanding both the proposed benefit and the specific questions that public catalog pages cannot answer.